ISSN:
1569-8041
Keywords:
cyclophosphamide
;
dose intensity
;
doxorubicin
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Background:CHOP is accepted as the gold standard for first linechemotherapy of aggressive non-Hodgkin's lymphoma (NHL). A dose-escalationstudy of CHOP was conducted to determine the maximal tolerated dose (MTD) andtoxicity profile of CHOP at three-week intervals with or without prophylacticrecombinant human granulocyte colony-stimulating factor (rHuG-CSF) in patientswith aggressive NHL. Patients and methods:The doses of drugs were escalated from 50mg/m2 to 70 mg/m2 for doxorubicin and from 750mg/m2 to 2250 mg/m2 for cyclophosphamide, withconventional doses of vincristine and oral prednisolone. After the MTD wasdetermined without rHuG-CSF, dose escalation was conducted with prophylacticrHuG-CSF. Results:Thirty-three patients with NHL were enrolled into thestudy. The MTD without prophylactic rHuG-CSF was 70 mg/m2 ofdoxorubicin and 1250 mg/m2 of cyclophosphamide, with neutropeniaas a dose-limiting toxicity. The MTD with prophylactic rHuG-CSF was 70mg/m2 of doxorubicin and 2250 mg/m2 of cyclophosphamide.The overall response rate was 100% (76% complete response and24% partial response). Progression-free survival and overall survivalat five years were 45% and 66%, respectively. Conclusions:Significant dose escalation of doxorubicin andcyclophosphamide was feasible with prophylactic rHuG-CSF. The efficacy ofdose-escalated CHOP should be compared with that of standard CHOP.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1023/A:1008361513544
Permalink
